This panel moderated by Dr Andrew Baum, Citi and recorded at the 5th annual IO360° Summit discusses the preparation of an IPO, straight licensing with the transition to a public company and decision making on prioritization within portfolios. 

Panelists include:

David Epstein, Flagship PioneeringDan Passeri, Cue Biopharma

Save the date for the 6th annual Immuno-Oncology 360° Summit on February 26-28, 2020 at the Crowne Plaza Times Square in New York City. Learn more at www.io360summit.com